Patents Examined by Valarie E Bertoglio
-
Patent number: 11643638Abstract: Provided are a method for producing stem cell-derived extracellular vesicles by using a three-dimensional cell culture process, use of three-dimensional cell aggregates of stem cells in producing extracellular vesicles, a culture of three-dimensional cell aggregates of stem cells comprising a high concentration of extracellular vesicles, and a pharmaceutical composition comprising the culture.Type: GrantFiled: April 29, 2016Date of Patent: May 9, 2023Assignees: Samsung Electronics Co., Ltd., S & E Bio CorporationInventors: Jae Min Cha, Oh Young Bang, Gyeong Joon Moon, Eun Kyoung Shin
-
Patent number: 11634690Abstract: An object of the present invention is to provide a material capable of further accelerating growth of pluripotent stem cells, such as pluripotent stem cells, without impairing pluripotency thereof. In other words, the invention is an agent for accelerating growth of pluripotent stem cells, containing a ?-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof as an active ingredient; and is a method for culturing pluripotent stem cells, including culturing pluripotent stem cells in a culture medium that contains a ?-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof.Type: GrantFiled: January 31, 2018Date of Patent: April 25, 2023Assignee: ORIENTAL YEAST CO., LTD.Inventors: Jun Nojima, Hidenori Matsuo, Yuriko Furuya, Hisataka Yasuda
-
Patent number: 11629337Abstract: The present invention relates to a method for preparing commercial scale quantities of canine functional beta cells and to the establishment of cell lines from immature canine pancreatic tissues. It also relates to a method of diagnosis using canine beta cell tumours or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing generating canine Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation.Type: GrantFiled: May 11, 2017Date of Patent: April 18, 2023Assignee: ANIMAL CELL THERAPY—ACTInventor: Paul Czernichow
-
Patent number: 11624052Abstract: The present invention provides a primary cell culture which combines a cell culture medium and cells derived from a hypertrophied androgenic gland (AG) of a decapod crustacean. The invention also provides methods for obtaining an all-female progeny by initially injecting/transplanting the primary cell culture to a genetic-female to obtain a male-Neo-male.Type: GrantFiled: February 24, 2020Date of Patent: April 11, 2023Assignee: ENZOOTIC HOLDINGS LTD.Inventors: Assaf Shechter, Ohad Rosen, Amir Sagi
-
Patent number: 11607425Abstract: The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting a human kidney precursor cell into the metanephros; and a step of advancing development of the metanephros, which is a step in which the transplanted human kidney precursor cell is differentiated and matured to form a part of the kidney.Type: GrantFiled: June 8, 2017Date of Patent: March 21, 2023Assignees: BIOS Co., LtdInventors: Takashi Yokoo, Shuichiro Yamanaka
-
Patent number: 11603518Abstract: Methods for differentiating human pluripotent stem cells to dorsal neuroectoderm progenitors and further to glial progenitor cells and oligodendrocyte progenitor cells (OPCs) using inhibitors of BMP signaling and MAPK/ERK signaling are provided. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for efficiently differentiating human pluripotent stem cells to OPCs in the absence of the ventralizing morphogen SHH or a SHH signaling activator. The methods of the present disclosure reproducibly produce dorsal neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.Type: GrantFiled: January 23, 2020Date of Patent: March 14, 2023Assignee: ASTERIAS BIOTHERAPEUTICS, INC.Inventors: Kento Onishi, Nathan C. Manley, Craig R. Halberstadt, Erik M. Whiteley
-
Patent number: 11582957Abstract: The invention relates to a genetically modified mouse comprising a heterozygous mutation of Tardbp (TDP-43) gene in that the Asn at amino acid 390 in TDP-43 is substituted with an amino acid that is different from Asn, wherein the genetically modified mouse exhibits Amyotrophic lateral sclerosis (ALS)-like phenotypes, TDP-43 proteinopathies and/or motor neuron degeneration. The invention also so relates to an isolated spinal cord motor neuron differentiated from an embryonic stem cell (ESC) that is obtained from an offspring of a genetically modified mouse according to the invention. Methods for identifying an agent alleviating and/or suppressing ALS-TDP pathogenesis are also disclosed.Type: GrantFiled: April 17, 2019Date of Patent: February 21, 2023Assignee: ACADEMIA SINICAInventors: Che-Kun James Shen, Shih-Ling Huang
-
Patent number: 11578306Abstract: Provided are methods for propagating mesenchymal stem cells (MSC), and particularly adipose derived stem cells, including incubating isolated cells obtained from a tissue or organ including MSC in a growth medium including an apoptosis inducing agent, under specified conditions. Further provided is an isolated cell population and kits for performing the methods.Type: GrantFiled: September 22, 2016Date of Patent: February 14, 2023Assignee: CELLECT BIOTHERAPEUTICS LTD.Inventors: Tal Almog, Shai Yarkoni
-
Patent number: 11578310Abstract: A method for producing CD4/CD8 double-positive T cells, comprising the steps of: (1) culturing pluripotent stem cells in a medium to induce hematopoietic progenitor cells; and (2) culturing the hematopoietic progenitor cells obtained in the step (1) in a medium containing a p38 inhibitor and/or SDF-1 to induce CD4/CD8 double-positive T cells.Type: GrantFiled: June 21, 2017Date of Patent: February 14, 2023Assignee: KYOTO UNIVERSITYInventors: Shin Kaneko, Yutaka Yasui, Shoichi Iriguchi, Tatsuki Ueda
-
Patent number: 11572545Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: GrantFiled: June 16, 2017Date of Patent: February 7, 2023Assignee: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Patent number: 11566221Abstract: Embodiments herein provide methods of differentiating neural stem cells to neuronal cells while concomitantly retarding neural stem cell proliferation. Resultant cultures demonstrate reduced clumping of cells, increased purity of neuronal cells and accelerated electrophysiology as compared to control methods.Type: GrantFiled: October 20, 2017Date of Patent: January 31, 2023Assignee: Life Technologies CorporationInventors: Soojung Shin, Yiping Yan, Daniel Beacham
-
Patent number: 11560546Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motor neurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.Type: GrantFiled: February 20, 2019Date of Patent: January 24, 2023Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Stuart Chambers, Lorenz Studer
-
Patent number: 11559605Abstract: The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting, into the metanephros, a kidney precursor cell derived from a non-human animal which is allogeneic or xenogeneic to the non-human animal; and a step of advancing development of the metanephros, which is a step in which the transplanted kidney precursor cell is differentiated and matured to form a part of the kidney.Type: GrantFiled: June 8, 2017Date of Patent: January 24, 2023Assignees: BIOS CO., LTDInventors: Takashi Yokoo, Shuichiro Yamanaka
-
Patent number: 11542315Abstract: Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.Type: GrantFiled: August 31, 2017Date of Patent: January 3, 2023Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Hannah E. Bowrey, Gary Aston-Jones
-
Patent number: 11542473Abstract: Maturation signals provided via cyclic adenosine monophosphate (cAMP)/Exchange proteins activated by cAMP (Epac) signaling during in vitro generation of blood cells from reprogrammed cells or pluripotent stem cells achieve superior function of hematopoietic cells differentiated from stem cells. The cAMP/Epac signaling enables an increased efficiency of production of precursor to blood and to blood cells. These generated blood cells can be utilized for therapeutics, treatments, disease prevention, drug discovery, personalized medicine, regenerative medicine, cell and tissue generation, universal donor banks and related methods and compositions.Type: GrantFiled: October 21, 2016Date of Patent: January 3, 2023Assignee: Amniotics ABInventors: Shobhit Saxena, Roger Emanuel Rönn, Niels-Bjarne Woods
-
Patent number: 11534502Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.Type: GrantFiled: August 30, 2017Date of Patent: December 27, 2022Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.Inventors: Yuelei Shen, Yang Bai, Rui Huang, Yanan Guo, Xiaofei Zhou, Meiling Zhang
-
Patent number: 11505806Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.Type: GrantFiled: May 31, 2019Date of Patent: November 22, 2022Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.Inventors: Yuelei Shen, Chaoshe Guo, Yang Bai, Jiawei Yao, Meiling Zhang, Xiaofei Zhou
-
Patent number: 11505781Abstract: The present invention relates to culture media for oocytes and uses thereof. Specifically, media for culturing an oocyte in vitro are disclosed, wherein said media comprise granulocyte macrophage-colony stimulating factor (GM-CSF). The presence of GM-CSF in the media increases the maturation and/or developmental competence of the oocyte making it suitable for use in subsequent assisted reproductive technologies. Methods for increasing the maturation and/or developmental competence of an oocyte are also disclosed.Type: GrantFiled: December 8, 2017Date of Patent: November 22, 2022Inventor: Mark Brenton Nottle
-
Patent number: 11492644Abstract: Expression of exogenous SNAI2, EYA1 and SIX1 genes in a cell, tissue or organ not normally having nephron progenitor activity, induces or re-programs that cell to have or subsequently develop nephron progenitor activity. Nephron progenitors induced 5 by expression of SNAI2, EYA1 and SIX1 may be used for the production of nephron cells and tissues that are useful in treatment of kidney disorders, kidney regeneration, kidney transplantation, bioprinting and nephrotoxocity testing.Type: GrantFiled: May 24, 2018Date of Patent: November 8, 2022Assignees: MURDOCH CHILDRENS RESEARCH INSTITUTE, VANDERBILT UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OE VETERANS AFFAIRSInventors: Melissa Little, Jessica Vanslambrouck, Lauren Woodard, Matthew Wilson
-
Patent number: 11464806Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.Type: GrantFiled: January 28, 2020Date of Patent: October 11, 2022Assignee: JUNCTUCELL BIOMED MANUFACTURING GMBHInventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss